secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029090
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharmaceuticals cuts workforce 36% in realignment plan; expects $3.5M cash charges
--------------------------------------------------------------------------------

- Board approved Realignment Plan reducing workforce ~36%, affecting employees supporting Byfavo, Barhemsys, Ryanodex.
- Estimated $3.5M cash charges: $3.1M severance/healthcare, $0.4M retention benefits; recorded in Q1 2024.
- Plan substantially complete by end of Q1 2024; company to continue commercialization with reduced team plus oncology sales.
- Also performing impairment analysis over certain long-lived assets and inventory; may record non-cash impairment charges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/0001104659-24-029090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/tm247572d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer